Related Articles by Review for PMID: 39083631

Year	Number of Results
2012	35
2017	7
2018	6
2019	2
2020	10
2021	6
2022	2
2023	6
2024	10
2025	3

1

[No authors listed] [No authors listed] 2024 Jul 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2024 Jul 5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 39083631 Free Books & Documents. Review.

2

Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction.

Qamar S, Mallik R, Makaronidis J. Qamar S, et al. touchREV Endocrinol. 2024 Oct;20(2):62-71. doi: 10.17925/EE.2024.20.2.9. Epub 2024 Feb 9. touchREV Endocrinol. 2024. PMID: 39526054 Free PMC article. Review.

3

Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.

Pressley H, Cornelio CK, Adams EN. Pressley H, et al. J Pharm Technol. 2022 Dec;38(6):368-373. doi: 10.1177/87551225221116010. Epub 2022 Aug 30. J Pharm Technol. 2022. PMID: 36311304 Free PMC article. Review.

4

Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis.

Ferraz Barbosa B, Aquino de Moraes FC, Bordignon Barbosa C, Palavicini Santos PTK, Pereira da Silva I, Araujo Alves da Silva B, Cristine Marques Barros J, Rodríguez Burbano RM, Pereira Carneiro Dos Santos N, Rodrigues Fernandes M. Ferraz Barbosa B, et al. J Pers Med. 2023 Oct 4;13(10):1460. doi: 10.3390/jpm13101460. J Pers Med. 2023. PMID: 37888071 Free PMC article. Review.

5

Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.

Trapp CM, Censani M. Trapp CM, et al. Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):136-140. doi: 10.1097/MED.0000000000000798. Epub 2023 Feb 1. Curr Opin Endocrinol Diabetes Obes. 2023. PMID: 36722447 Free PMC article. Review.

6

Setmelanotide: First Approval.

Markham A. Markham A. Drugs. 2021 Feb;81(3):397-403. doi: 10.1007/s40265-021-01470-9. Drugs. 2021. PMID: 33638809 Review.

7

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Ryan DH. Ryan DH. J Obes Metab Syndr. 2021 Sep 30;30(3):196-208. doi: 10.7570/jomes21033. J Obes Metab Syndr. 2021. PMID: 34518444 Free PMC article. Review.

8

Setmelanotide (Imcivree) for rare genetic forms of obesity.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Jul 26;63(1629):e3-e4. Med Lett Drugs Ther. 2021. PMID: 34544109 Review. No abstract available.

9

Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).

Hainer V, Aldhoon Hainerová I, Kunešová M, Taxová Braunerová R, Zamrazilová H, Bendlová B. Hainer V, et al. Physiol Res. 2020 Sep 30;69(Suppl 2):S245-S254. doi: 10.33549/physiolres.934512. Physiol Res. 2020. PMID: 33094623 Free PMC article. Review.

10

Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.

Kühnen P, Krude H, Biebermann H. Kühnen P, et al. Trends Mol Med. 2019 Feb;25(2):136-148. doi: 10.1016/j.molmed.2018.12.002. Epub 2019 Jan 11. Trends Mol Med. 2019. PMID: 30642682 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 39083631

51 results

Results by year